- NCIt
- C4958
Loading cancer entity…
Loading cancer entity…
Clinical trials
32 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma | not yet recruiting | Phase 1 / Phase 2 | 113 | Jubilant Therapeutics Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07694986 | Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD | recruiting | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02422641 | Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis | recruiting | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2026source: clinicaltrials
| NCT03175432 |
| Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases |
| active not recruiting |
| Phase 2 |
| 29 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jun 25, 2026 |
| clinicaltrials |
| NCT04588545 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | active not recruiting | Phase 1 / Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05305365 | Study Assessing QBS72S For Treating Brain Metastases | active not recruiting | Phase 2 | 21 | Stanford UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05800275 | Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease(ETIC-LM) | recruiting | Phase 2 | 30 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | terminated | Phase 2 | 17 | University of Alabama at BirminghamOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |